Last reviewed · How we verify
SC interferon beta-1b
At a glance
| Generic name | SC interferon beta-1b |
|---|---|
| Also known as | Betaferon, Extavia |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PHASE4)
- A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis
- Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis (PHASE3)
- An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS (PHASE4)
- RNF and Betaseron® Tolerability Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC interferon beta-1b CI brief — competitive landscape report
- SC interferon beta-1b updates RSS · CI watch RSS
- Biogen portfolio CI